Cardiac side-effects of cancer chemotherapy

International Journal of Cardiology

Volumn 144, Issue 1, 2010, Pages 3-15

  Monsuez, Jean Jacques ^a   Charniot, Jean Christophe ^a   Vignat, Noëlle ^a   Artigou, Jean Yves ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Cancer; Cardiotoxicity; Chemotherapy

Indexed keywords

ACLARUBICIN; ALEMTUZUMAB; AMLODIPINE; AMSACRINE; ARSENIC TRIOXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARVEDILOL; CETUXIMAB; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLYCERYL TRINITRATE; IDARUBICIN; IFOSFAMIDE; ISOSORBIDE DINITRATE; MITOXANTRONE; PACLITAXEL; RETINOIC ACID; RITUXIMAB; SILDENAFIL; TRASTUZUMAB; UNINDEXED DRUG; ZORUBICIN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ANTERIOR MYOCARDIAL INFARCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRADYCARDIA; BREAST CANCER; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG STRUCTURE; ECHOCARDIOGRAPHY; FEVER; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; LUNG NON SMALL CELL CANCER; MYOCARDITIS; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPERTENSION; OVARY CANCER; OXIDATIVE STRESS; PATIENT MONITORING; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPHYLAXIS; QT PROLONGATION; RETINOIC ACID SYNDROME; REVIEW; SCINTIANGIOGRAPHY; SINUS BRADYCARDIA; STEM CELL; SUPRAVENTRICULAR PREMATURE BEAT; TACHYCARDIA; THORAX PAIN; TORSADE DES POINTES; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 77956129095     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.03.003     Document Type: Review

References (121)

1. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229
2. T. Van Dyke P53 and tumor suppression N Engl J Med 356 2007 79 81
3. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1996 47 58
4. P.K. Singal Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905
5. J.B. Caulfield, and V. Bittner Cardiac matrix alterations induced by adriamycin Am J Pathol 133 1988 298 305
6. M.A. Sussman, S.F. Hamm-Alvarez, P.M. Vilatta, S. Welch, and L. Kedes Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration Circ Res 80 1997 52 61
7. Y. Hsiu-Chuan, T.D. Oberley, S. Vichitbandha, H.O. Ye-Shhi, and D.K. St Clair The protective role of manganese superoxide dismutase agains adriamycin-induced acute cardiac toxicity in transgenic mice J Clin Invest 98 1996 1253 1260
8. N. Sarvazyan Vizualisation od doxorubicin-induced oxidative stress in isolated cardiac myocytes Am J Physiol 271 1996 H2079 H2085
9. L. Wojnowski, B. Kulle, and M. Schirmer NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiomyopathy Circulation 112 2005 3754 3762
10. H. Lou, I. Danelisen, and P.K. Singal Involvement of mitogen activated protein kinases in adriamycin induced cardiomyopathy Am J Physiol 288 2005 H1925 H1930
11. M. Tokarska-Schlattner, M. Zaugg, and R. da Silva Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply Am J Physiol Heart Circ Physiol 289 2005 H37 H47
12. W. Zhu, Y. Zou, and R. Aikawa MAPK superfamily plays an important role in daunorubicin-induced apoptosis of cardiac myocytes Circulation 100 1999 2100 2107
13. D. Lebrecht, B. Setzer, U.P. Ketelsen, J. Haberstroh, and U.A. Walker Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy Circulation 108 2003 2423 2429
14. S. Negoro, H. Oh, and E. Tone Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase / Akt phosphorylation and Bcl-xL caspase-3 interaction Circulation 103 2001 555 561
15. S. Wang, E.A. Konorev, S. Kotamraju, J. Joseph, S. Kalivendi, and B. Kalyanaraman Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H2O2-and p53-dependent pathways J Biol Chem 279 2004 25535 25543
16. X. Liu, C.C. Chua, and J. Gao Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice Am J Physiol Heart Circ Physiol 286 2004 H933 H939
17. A. Aries, P. Paradis, C. Lefevre, and R.J. Schwartz Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity PNAS 101 2004 2975 2980
18. T. L'Ecuyer, Z. Allebban, R. Tomas, and R. Van de Heide Glutathione S-transferase overexpression protects against anthracyclin-induced H9C2 cell death Am J Physiol Heart Circ Physiol 286 2004 H2057 H2064
19. A. De Angelis, E. Piegari, and D. Cappetta Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function Circulation 121 2010 276 292
20. H. Ito, S.C. Miller, M.E. Billingham, H. Akimoto, S.V. Torti, and R. Wade Doxorubicin selectively inhibits muscle gene expression in cardiac muscles cells in vivo and in vitro Proc Natl Acad Sci USA 87 1990 4275 4279
21. M.A. Sussman, S.F. Hamm-alvarez, P.M. Vilalta, S. Welch, and L. Kedes Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration Circ Res 80 1997 52 61
22. M. Korth, and Yong-Xiao Wang Effects of doxorubicin on exitation-contraction coupling in Guinea pig ventricular myocardium Circ Res 76 1995 645 653
23. M. Arai, A. Yoguchi, and T. Takizawa Mechanisms of doxorubicin-induced inhibition of sarcoplasmic Ca2+-ATPase gene transcription Circ Res 86 2000 8 15
24. J.H. Doroshow Doxorubicin-induced cardiac toxicity N Engl J Med 324 1991 843 844
25. J. Pihkala, U.M. Saarinen, U. Lundström, K. Virtanen, K. Virkola, and M.A. Simes Myocardial function in children and adolescents after therapy with anthracyclins and chest irradiation Eur J Cancer 32A 1996 97 103
26. M.F. Stoddart, J. Seeger, N.E. Liddel, T.J. Hadley, D.M. Sullivan, and J. Wupersmith Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans J Am Coll Cardiol 20 1992 62 69
27. L.J. Steinherz, P.G. Steinherz, C.T.C. Tan, G. Heller, and L. Murphy Cardiac toxicity 4 to 20 years after completing anthracyclin therapy JAMA 266 1991 1672 1677
28. P.G. Horan, M.F. McMullin, and P.P. McKeown Anthracycline cardiotoxicity Eur Heart J 27 2006 1137 1138
29. M.R. Bristow, J.W. Mason, M.E. Billingham, and J.R. Daniels Dose-effect and structure-function relationships in doxorubicin cardiomyopathy Am Heart J 102 1981 709 718
30. R.S. Benjamin Rationale for the use of mitoxantrone in the older patient: cardiac toxicity Semin Oncol 22 Suppl 1 1995 11 13
31. J.M. Rowe, A.Y. Chang, and J.M. Benett Treatment of refractory leukaemia with aclacinomycin A Bone Marrow Transplant 4 Suppl 3 1989 45 48
32. R.B. Weiss, A.J. Grillo-Lopez, S. Marsoni, J.G. Posada, F. Hess, and B.J. Ross Amsacrine-associated cardiotoxicity: an analysis of 82 cases J Clin Oncol 4 1986 919 926
33. S.E. Lipshultz, S.D. Colan, R.D. Gelber, A.R. Perez-Atayde, S.E. Sallan, and S.P. Sanders Late cardiac effects of doxorubicin therapy for acute lymphoblastc leukaemia in childhood N Engl J Med 324 1991 808 815
34. C. Huang, X. Zhang, and J.M. Ramil Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and revascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice Circulation 121 2010 675 683
35. B.H. Lee, L.S. Goodenday, G.J. Muswick, W.A. YasnoFF, R.F. Leighton, and R.T. Skeel Alterations in left ventricular diastolic function with doxorubicin therapy J Am Coll Cardiol 9 1987 184 188
36. B. Marchandise, E. Schroeder, A. Bosly, C. Doyen, P. Weynants, and P. Kremer Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics Am Heart J 118 1989 92 98
37. D. Johnson, H. Perrault, A. Fournier, J.M. Leclerc, J.L. Bigras, and A. Davignon Cardiovascular response to dynamic submaximal exercise in children previously treated with anthracyclins Am Heart J 133 1997 169 173
38. S.E. Klewer, S.J. Goldberg, R.L. Donnerstein, R.A. Berg, and J.J. Hutter Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer J Am Coll Cardiol 19 1992 394 401
39. M. Civelli, D. Cardinale, A. Martinoni, G. Lamantia, N. Colombo, and A. Colombo Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity Int J Cardiol 111 2006 120 126
40. S. Tassan-Mangina, D. Codorean, M. Metivier, B. Costa, C. Himberlin, and C. Jouannaud Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr 7 2006 141 146
41. G. Mercuro, C. Caddeddu, and E. Piras Early epirubicin myocardial dysfunction revealed by serial tissue doppler echocardiography. Correlation with inflammatory and oxidative stress markers Oncologist 12 2007 1124 1133
42. J. Ganame, P. Claus, and B. Eyskens Acute cardiac functional and morphological changes after anthracycline infusions in children Am J Cardiol 99 2007 974 977
43. R.G. Schwartz, W.B. Mckenzie, J. Alexander, P. Sager, A. D'Soua, and A. Manatunga Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-years experience using serial radionuclide angiography Am J Med 82 1987 1109 1118
44. K. Oberholzer, R.P. Kunz, M. Dittrich, and M. Thelen Anthracyclin-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer Rofo 176 2004 1245 1250
45. G. Daugaard, U. Lassen, P. Bie, E.B. Pedersen, K.T. Jensen, and U. Abilgaard Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction Eur J Heart Fail 7 2005 87 93
46. I. Germanakis, M. Kalmanti, and F. Parthenakis Correlation of plasma N-terminal pro-brain natriuretic peptide levels with ventricle mass in children treated with anthracyclins Int J Cardiol 108 2006 212 215
47. A. Kouloubinis, L. Katlamanis, N. Ziras, S. Sofroniadou, K. Makaritsis, and S. Adamopoulos ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy Int J Cardiol 122 2007 195 201
48. D. Cardinale, M.T. Sandri, A. Colombo, N. Colombo, M. Boeri, and G. Lamantia Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
49. S.S. Legha, R.S. Benjamin, and B. Mackay Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion Ann Intern Med 96 1982 133 139
50. J. Shapira, M. Godfried, M. Lishner, and M. Ravid Reduced cardiotoxicity of doxorubicin by a 6-hours infusion regimen Cancer 65 1990 870 873
51. M. Lotrionte, G. Palazzoni, and R. Natali Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end points : rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study Int J Cardiol 135 2009 72 77
52. W.C. Reeves, J.W. Griffith, M.A. Wood, and L. Whitesell Exacerbation of doxorubicin cardiotoxicity by digoxin administration in an experimental rabbit model Int J Cancer 45 1990 731 736
53. S. Yamanaka, T. Tatsumi, J. Shiraishi, A. Mano, N. Keira, and S. Matoba Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes J Am Coll Cardiol 41 2003 870 878
54. D. Outomuro, D.R. Grana, F. Azzato, and J. Milei Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol 117 2007 6 15
55. T.G. Neilan, D.S. Jassal, M.F. Scully, G. Chen, C. Deflandre, and H. McAllister Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression Eur Heart J 27 2006 1251 1256
56. P.W. Fisher, F. Salloum, A. Das, H. Hyder, and R.C. Kukreja Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity Circulation 111 2005 1601 1610
57. N. Kalay, E. Basar, and I. Ozdugru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
58. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, and M.T. Civelli Prevention of high dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481
59. H. Nakamae, K. Tsumura, Y. Terada, M. Nakane, K. Ohta, and T. Yamane Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498
60. N. Siveski-Iliskovic, M. Hill, D.A. Chow, and P.K. Singal Probucol protects against adriamycin cardiomyopathy without interfering with its anti-tumor properties Circulation 91 1995 10 15
61. R.S. Cvetkovic, and L.J. Scott Dexrazoxane. A review of its use for cardioprotection during anthracycline chemotherapy Drugs 65 2005 1005 1024
62. J.L. Speyer, M.D. Green, J. Sanger, A. Zeleniuch-Jacquotte, E. Kramer, and M. Rey A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin induced cardiac toxicity in women with breast cancer Cancer Treat Rev 17 1990 161 163
63. S.M. Swain, F.S. Whaley, M.C. Gerber, S. Weisberg, M. York, and D. Spicer Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 1997 1318 1340
64. M. Venturini, A. Michelotti, L. Del Mastro, L. Gallo, F. Carnino, and O. Garrone Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer J Clin Oncol 14 1996 3112 3120
65. F. Testore, S. Milanese, and M. Ceste Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclins in adjuvant setting Am J Cardiovasc Drugs 8 2008 257 263
66. L.H. Wexler, M.P. Andrich, D. Venzon, S.L. Berg, L. Weaver-McClure, and C.C. Chen Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin J Clin Oncol 14 1996 362 372
67. S.E. Lipshultz, and N. Rifai The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 351 2004 145 153
68. L. Elbl, H. Hrstkova, I. Tomaskova, B. Blazek, and J. Michalek Long term echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients Eur J Pediatr 164 2005 678 684
69. J.S. Gottdiener, J.R. Appelbaum, V.J. Ferrans, A. Deisseroth, and J. Ziegler Cardiotoxicity associated with high dose cyclophosphamide therapy Arch Intern Med 141 1981 758 763
70. E.T.H. Yeh, A.T. Tong, and D.J. Lenihan Cardiovascular complications of cancer therapy Circulation 109 2004 3122 3131
71. A.C. Braverman, J.H. Antin, M.T. Plappert, E.F. Cook, and R.T. Lee Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens J Clin Oncol 9 1991 1215 1223
72. Z.N.M. Quezado, W.H. Wilson, R.E. Cunnion, M.M. Parker, D. Reda, and G. Bryant High-dose ifosfamide is associated with severe, reversible cardiac dysfunction Ann Intern Med 118 1993 31 36
73. Y. Nieto, P. Cagnoni, S.I. Bearman, E.J. Shpall, S. Mathes, and R.B. Jones Cardiac toxicity following high-dose cyclophosphamide, cisplatin and BCNU for breast cancer Biol Blood Marrow Transpl 6 2000 198 203
74. M. De Forni, M.C. Mallet-Martino, P. Jaillais, R.E. Shubinski, J.M. Bachaud, and L. Lemaire Cardiotoxicity of high-dose continuous infusion fluorouracil : a prospective clinical study J Clin Oncol 10 1992 1795 1801
75. R.J. Luwaert, O. Descamps, F. Majois, J.M. Chaudron, and M. Beauduin Coronary artery spasm induced by 5-fluorouracil Eur Heart J 12 1991 468 470
76. W.F. Cathcart-Rake, and W.E. Mowery Intrapericardial infusion of 5-fluorouracil Cancer 67 1991 735 737
77. N. Frickhofen, F.J. Beck, B. Jung, H.G. Fuhr, H. Andrasch, and M. Sigmund Capecitabine can induce acute coronary syndrome similar to 5-fluorouracile Ann Oncol 13 2002 797 801
78. S. Coughlin, S. Das, J. Lee, and J. Cooper Capecitabine induced vasospastic angina Int J Cardiol 130 2008 e34 e36
79. M. Ng, D. Cunningham, and A.R. Norman The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer Eur J Cancer 41 2005 1542 1546
80. E.K. Rowinsky, W.P. McGuire, T. Guarneri, J.S. Fisherman, M.C. Christian, and R.C. Donehower Cardiac disturbances during the administration of Taxol J Clin Oncol 9 1991 1704 1712
81. A. Jekunen, P. Heikkila, A. Maiche, and S. Pyrhonen Paclitaxel-induced myocardial damage detected by electron microscopy Lancet 343 1994 727 728
82. M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J.P. Guastalla, and C. Weaver Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2005 2302 2313
83. D.T. Vogl, E. Glatstein, J.R. Carver, S.J. Schuster, E.A. Stadtmauer, and S. Luger Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation Leuk Lymphoma 46 2005 1313 1320
84. M.S. Tallman, J.W. Andersen, C.A. Schiffer, F.R. Appelbaum, J.H. Feusner, and A. Ogden Clinical description of 44 patients with acute promyelocytic leukaemia who developed the retinoic acid syndrome Blood 95 2000 90 95
85. P. Westervelt, R.A. Brown, D.R. Adkins, H. Khoury, P. Curtin, and D. Hurd Sudden death among patients with acute promyelocytic leukaemia treated with arsenic trioxide Blood 98 2001 206 211
86. J. Mendelsohn, and J. Baselga Epidermal growth factor receptor targeting in cancer Sem Oncol 33 2006 369 385 (Pubitemid 44142736)
87. D.E. Gerber Targeted therapies: a new generation of cancer treatments Am Fam Physician 77 2008 311 319
88. K.I. Pritchard, L.E. Shepherd, F.P. O'Malley, I.L. Andrulis, D. Tu, and V.H. Bramwell HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2006 2103 2111
89. M.H. Chen, R. Kerkelä, and T. Force Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapy Circulation 117 2008 84 95
90. K.R. Chien Herceptin and the heart- A molecular modifier of cardiac failure N Engl J Med 354 2006 789 790
91. L.P. Grazette, W. Boecker, T. Matsui, M. Semigran, T.L. Force, and R.J. Hajjar Inhibition of Erb2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy J Am Coll Cardiol 44 2004 2231 2238
92. L.I. Gordon, M.A. Burke, A.T. Singh, S. Prachand, E.D. Lieberman, and L. Sun Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways J Biol Chem 284 2009 2080 2087
93. M.J. Piccart-Gebhart, and M. Procter et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
94. A. Seidman, C. Hudis, M.K. Pierri, S. Shak, V. Paton, and M. Ashby Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221
95. M.S. Ewer, M.T. Vooletich, J.B. Durand, M.L. Woods, J.R. Davis, and V. Valero Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 2005 7820 7826
96. M.S. Ewer, and S.M. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2005 2900 2902
97. A.L. Jones, M. Barlow, P.J. Barrett-Lee, P.A. Canney, I.M. Gilmour, and S.D. Robb Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
98. D. Wadhwa, N. Fallah-Rad, D Grenier, M. Krahn, T. Fang, and R. Ahmadie Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study Breast Cancer Res Treat 117 2009 357 364
99. N. Fallah-Rad, M. Lytwyn, T. Fang, I. Kirkpatrick, and D.S. Jassal Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 2008 5
100. P. Rastogi, J. Jeong, C.E. Geyer, J.P. Costantino, E.H. Romond, and M.S. Ewer Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC) → paclitaxel (T) vs AC → T with trastuzumab (H) J Clin Oncol 25 2007 Abstract LBA513
101. T.M. Suter, M. Procter, D.J. van Veldhuysen, M. Muscholl, J. Bergh, and C. Carlomagno Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial J Clin Oncol 25 2007 3859 3865
102. M. Scartozzi, E. Galizia, and S. Chiorrini Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first line bevacizumab Ann Oncol 7 2008 epub October
103. A.L. Basquiera, A.R. Berretta, J.J. Garcia, and E.D. Palazzo Coronary ischemia related to alemtuzumab therapy Ann Oncol 19 2004 161 168
104. S.R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. A meta-analysis JAMA 300 2008 2277 2285
105. R. Kerkelä, L. Grazette, R. Ullrich, C. Iliescu, R. Patten, and C. Beahm Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916
106. K. Strebhardt, and A. Ullrich Another look at imatinib mesylate N Engl J Med 355 2006 2481 2482
107. G. Turrisi, F. Montagnani, C. Marinozzi, L. Bolognese, and G. Fiorentini Congestive heart failure during imatinib mesylate treatment Int J Cardiol 2009 Epub ahead of print
108. T.F. Chu, M.A. Rupnick, R. Kerkelä, S.M. Dallabrida, D. Zurakowski, and L. Nguyen Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
109. A.Y. Khakoo, C.M. Kassiotis, N. Tannir, J.C. Plana, M. Halushka, and C. Bickford Heart failure associated with sunitinib malate Cancer 112 2008 2500 2508
110. M.L. Telli, R.M. Witteles, G.A. Fisher, and S. Srinivas cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 2008 1613 1618
111. M. Schmidinger, C.C. Zielinski, U.M. Vogl, A. Bojic, C. Schukro, and M. Ruhsam Cardiac toxicity of sunitinib and sorafenib in patients with metaststic renal cell cardcinoma J Clin Oncol 26 2008 5204 5212
112. H. Joensuu Cardiac toxicity of sunitinib Lancet 370 2007 1978 1980
113. X. Zhu, K. Stergiopoulos, and S. Wu risk of hypertension and renal dysfunction with angiogenesis inhibitor sunitinib : systematic review and meta-analysis Acta Oncol 20 2008 1 9
114. M.K. Wong, and A. Jarkowski Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature Pharmacotherapy 29 2009 473 478
115. S. Wu, J.J. Chen, A. Kudelka, J. Lu, and X. Zhu Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and mata-analysis Lancet Oncol 9 2008 117 123
116. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
117. E.A. Perez, M. Koehler, J. Byrne, A.J. Preston, E. Rappold, and M.S. Ewer Cardiac safety of lapatinib pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 2008 679 686
118. E.T.H. Yeh, and C.L. Bickforf Cardiovascular complications of cancer therapy J Am Coll Cardiol 53 2009 2231 2247
119. M.L. Diaz, A. Villanueva, G. Bastarrika, and B. Zudaire Garcia del Barrio L, Noguera JJ. Non-electrocardiogram-gated multidetector-row computed tomography findings of cardiac pathology in oncologic patients Curr Probl Diagn Radiol 38 2009 206 217
120. D. Cardinale, A. Colombo, G. Lamantia, N. Colombo, M. Civelli, and G. De Giacomi Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacological therapy J Am Coll Cardiol 55 2010 213 220
121. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150